vs
Side-by-side financial comparison of Burke & Herbert Financial Services Corp. (BHRB) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $86.5M, roughly 1.9× Burke & Herbert Financial Services Corp.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 4.9%). Over the past eight quarters, Burke & Herbert Financial Services Corp.'s revenue compounded faster (81.1% CAGR vs 10.6%).
Burke & Herbert Financial Services Corp is a U.S.-based regional financial holding company, offering personal and commercial banking, wealth management, residential mortgage lending, and small business financing services. Its core market covers Virginia and adjacent Mid-Atlantic regions, serving retail consumers, SMEs, and high-net-worth clients.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
BHRB vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.5M | $168.4M |
| Net Profit | $30.2M | — |
| Gross Margin | — | — |
| Operating Margin | 43.8% | 50.6% |
| Net Margin | 34.9% | — |
| Revenue YoY | 4.9% | 143.7% |
| Net Profit YoY | 52.8% | — |
| EPS (diluted) | $1.98 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.5M | $168.4M | ||
| Q3 25 | $85.4M | $87.3M | ||
| Q2 25 | $87.1M | $82.4M | ||
| Q1 25 | $83.0M | $65.0M | ||
| Q4 24 | $82.5M | $69.1M | ||
| Q3 24 | $83.8M | $51.6M | ||
| Q2 24 | $69.3M | $73.8M | ||
| Q1 24 | $26.4M | $137.7M |
| Q4 25 | $30.2M | — | ||
| Q3 25 | $30.0M | $-31.3M | ||
| Q2 25 | $29.9M | $-12.7M | ||
| Q1 25 | $27.2M | $-40.5M | ||
| Q4 24 | $19.8M | — | ||
| Q3 24 | $27.6M | $-29.5M | ||
| Q2 24 | $-16.9M | $-61.9M | ||
| Q1 24 | $5.2M | $61.0M |
| Q4 25 | 43.8% | 50.6% | ||
| Q3 25 | 43.3% | -11.4% | ||
| Q2 25 | 42.7% | 8.6% | ||
| Q1 25 | 39.6% | -34.0% | ||
| Q4 24 | 24.6% | -6.4% | ||
| Q3 24 | 39.2% | -31.0% | ||
| Q2 24 | -27.5% | 3.5% | ||
| Q1 24 | 22.3% | 52.5% |
| Q4 25 | 34.9% | — | ||
| Q3 25 | 35.1% | -35.9% | ||
| Q2 25 | 34.3% | -15.4% | ||
| Q1 25 | 32.8% | -62.2% | ||
| Q4 24 | 24.0% | — | ||
| Q3 24 | 33.0% | -57.2% | ||
| Q2 24 | -24.4% | -83.9% | ||
| Q1 24 | 19.8% | 44.3% |
| Q4 25 | $1.98 | $0.32 | ||
| Q3 25 | $1.97 | $-0.16 | ||
| Q2 25 | $1.97 | $-0.06 | ||
| Q1 25 | $1.80 | $-0.21 | ||
| Q4 24 | $1.72 | $-0.14 | ||
| Q3 24 | $1.82 | $-0.15 | ||
| Q2 24 | $-1.41 | $-0.33 | ||
| Q1 24 | $0.69 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $854.6M | $-302.0M |
| Total Assets | $7.9B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $167.9M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $86.1M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | — | $144.8M | ||
| Q3 24 | — | $144.7M | ||
| Q2 24 | — | $189.3M | ||
| Q1 24 | — | $226.6M |
| Q4 25 | $854.6M | $-302.0M | ||
| Q3 25 | $822.2M | $-451.4M | ||
| Q2 25 | $780.0M | $-433.5M | ||
| Q1 25 | $758.0M | $-426.2M | ||
| Q4 24 | $730.2M | $-388.7M | ||
| Q3 24 | $738.1M | $-370.2M | ||
| Q2 24 | $693.1M | $-344.2M | ||
| Q1 24 | $319.3M | $-294.3M |
| Q4 25 | $7.9B | $465.9M | ||
| Q3 25 | $7.9B | $364.0M | ||
| Q2 25 | $8.1B | $347.1M | ||
| Q1 25 | $7.8B | $324.0M | ||
| Q4 24 | $7.8B | $343.8M | ||
| Q3 24 | $7.9B | $314.1M | ||
| Q2 24 | $7.8B | $352.3M | ||
| Q1 24 | $3.7B | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $107.9M | $45.2M |
| Free Cash FlowOCF − Capex | $96.2M | — |
| FCF MarginFCF / Revenue | 111.2% | — |
| Capex IntensityCapex / Revenue | 13.5% | 0.0% |
| Cash ConversionOCF / Net Profit | 3.57× | — |
| TTM Free Cash FlowTrailing 4 quarters | $164.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $107.9M | $45.2M | ||
| Q3 25 | $39.3M | $-4.3M | ||
| Q2 25 | $41.0K | $-31.4M | ||
| Q1 25 | $37.6M | $-22.6M | ||
| Q4 24 | $85.8M | $-35.0M | ||
| Q3 24 | $47.8M | $-35.3M | ||
| Q2 24 | $-46.0M | $-7.2M | ||
| Q1 24 | $7.1M | $53.8M |
| Q4 25 | $96.2M | — | ||
| Q3 25 | $35.4M | — | ||
| Q2 25 | $-3.4M | — | ||
| Q1 25 | $35.9M | — | ||
| Q4 24 | $81.2M | — | ||
| Q3 24 | $46.0M | $-35.5M | ||
| Q2 24 | $-47.0M | $-7.3M | ||
| Q1 24 | $5.6M | $53.8M |
| Q4 25 | 111.2% | — | ||
| Q3 25 | 41.5% | — | ||
| Q2 25 | -3.9% | — | ||
| Q1 25 | 43.2% | — | ||
| Q4 24 | 98.5% | — | ||
| Q3 24 | 55.0% | -68.7% | ||
| Q2 24 | -67.8% | -9.9% | ||
| Q1 24 | 21.2% | 39.0% |
| Q4 25 | 13.5% | 0.0% | ||
| Q3 25 | 4.5% | 0.0% | ||
| Q2 25 | 3.9% | 0.0% | ||
| Q1 25 | 2.1% | 0.0% | ||
| Q4 24 | 5.5% | 0.0% | ||
| Q3 24 | 2.1% | 0.3% | ||
| Q2 24 | 1.5% | 0.1% | ||
| Q1 24 | 5.7% | 0.1% |
| Q4 25 | 3.57× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 1.38× | — | ||
| Q4 24 | 4.33× | — | ||
| Q3 24 | 1.73× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.36× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHRB
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
